

Cassava Sciences, Inc.

Fact Sheet

S A V A

LISTED

NASDAQ

CASSAVA SCIENCES

QUICK REFERENCE

Cassava Sciences Inc.
NASDAQ: SAVA

Website: [www. CASSAVASCIENCES.com](http://www.CASSAVASCIENCES.com)

BUSINESS SUMMARY

Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

SCIENCE

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer's disease.

Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.

The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer's Disease.

We are now in clinical studies to test a new and promising scientific approach for the treatment and diagnosis of Alzheimer's disease. If you are interested in being notified about clinical trials, [click here](#).

Simufilam was developed in-house. Over the years, simufilam has been substantially funded by peer-review research grant awards from the National Institutes of Health (NIH).

SavaDx (formerly known as PTI-125Dx) is our blood-based diagnostic to detect Alzheimer's disease.

The goal of SavaDx is to make the detection of Alzheimer's disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.

We are developing SavaDx as a simple, accurate and quantitative blood-based diagnostic to detect and monitor Alzheimer's disease. If successful, we believe SavaDx has potential to make obsolete many of the current approaches for diagnosing Alzheimer's disease.

In blinded studies, our investigational diagnostic, SavaDx, detected >10-fold differences between patients with Alzheimer's and age-matched normal controls or young cognitively intact subjects (N=232).

This clinical-stage program is funded by research grants from the National Institutes of Health (NIH).

CONTACT INFORMATION

US Headquarters
7801 N. Capital of Texas Highway
Austin, TX 78731

Investor Relations Contact
Andrew Barwicki
516-662-9461/andrew@barwicki.com

Recent Press Releases (*Headlines and Excerpts*)

Cassava Sciences Responds to Media Reports

- *In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures.*
- *No government agency has informed Cassava Sciences that it has found any evidence of research misconduct or any other wrong-doing.*
- *No government agency has filed any charges against Cassava Sciences.*

July 27, 2022 -- Cassava Sciences, Inc. reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company. The media widely reported on these disclosures in 2021. All government requests for information were made in response to allegations of research misconduct that were made in 2021 by financially motivated short-sellers of the Company's stock.

On November 15, 2021, Cassava Sciences publicly disclosed that certain government agencies had asked for corporate information and documents. These were confidential requests. We have voluntarily been cooperating with government authorities. No government agency has informed us that Cassava Sciences, or anyone associated with us, has engaged in any wrongdoing.

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

- *\$209.7 Million Cash and Cash Equivalents at March 31, 2022*
- *Over 120 Patients Now Enrolled in Phase 3 Program*

May 05, 2022 -- Cassava Sciences, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer's disease. Simufilam is Cassava Sciences' lead drug candidate for the proposed treatment of Alzheimer's disease.

Net loss was \$17.5 million, or \$0.44 per share, compared to a net loss of \$3.5 million, or \$0.09 per share, for the same period in 2021. Net cash used in operations was \$23.5 million during the first quarter of 2022, including over \$10 million of contractual pre-payments. Pre-payments are amounts paid for in advance of future research and development (R&D) services.

"We're seeing an uptick in the rate of patient enrollment," said Remi Barbier, President & CEO. "In part, the pandemic challenged some clinical sites, from staffing shortages to operational gaps. We hope these challenges are in the rearview mirror as we continue to move forward with our Phase 3 studies of simufilam in Alzheimer's disease, while keeping an eye on the balance sheet."

Overview of On-going Phase 3 Clinical Program Our Phase 3 program consists of two double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer's disease. Both Phase 3 studies have Special Protocol Assessments (SPA) from the U.S. Food and Drug Administration.

A total of over 120 subjects have now been enrolled in our Phase 3 studies. Studies are being conducted in over 115 clinical trial sites across the U.S., Canada and Puerto Rico.

Overview of Each On-going Phase 3 Study - RETHINK-ALZ and REFOCUS-ALZ Our Phase 3 study called "RETHINK-ALZ" is designed to evaluate the safety and efficacy of oral simufilam 100 mg in enhancing cognition and slowing functional decline over 52 weeks. This randomized, double-blind, placebo-controlled study plans to enroll approximately 750 patients with mild-to-moderate Alzheimer's disease.

Cassava Sciences Invited to Participate in B. Riley Securities' Neuroscience Conference

- *Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern*

April 25, 2022 -- Cassava Sciences, Inc. announced that it has been invited to participate in the B. Riley Securities' Neuroscience Conference, a virtual event taking place on April 27-28, 2022.

Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities' equity research team on Wednesday, April 27, 2022, at 1:30 PM ET.

A webcast will be available on <https://www.webcaster4.com/Webcast/Page/2875/45359> or in the Investors page of Cassava Sciences' website for approximately 90 days following the event.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Cassava Sciences Inc.
NASDAQ: SAVA

WWW.CASSAVASCIENCES.COM

Barvicki Investor Relations • 30 Wall Street, 8 FL • New York, NY 10005

Deliver to: